Palexia

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol Hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a oral medication for oral use. It is used to treat moderate to severe acute pain in adult patients when other analgesics are insufficient.

GNH India supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Grünenthal Pharma Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palexia is an opioid analgesic that acts on the central nervous system to relieve pain. It is indicated for:

Acute postoperative pain: Provides relief following surgical procedures.
Chronic musculoskeletal pain: Helps manage persistent pain from conditions such as osteoarthritis.
Cancer‑related pain: Used as part of a multimodal regimen for cancer pain management.

How It Works

Tapentadol Hydrochloride works by dual action: it binds to mu‑opioid receptors, producing opioid‑mediated analgesia, and it inhibits the reuptake of norepinephrine, enhancing descending pain‑modulating pathways. This combined mechanism reduces the perception of pain without requiring high opioid receptor activation alone.

Side Effects

Tapentadol Hydrochloride may cause a range of adverse reactions.

Common Side Effects

Nausea: Mild to moderate upset stomach.
Dizziness: Light‑headed feeling, especially when standing quickly.
Constipation: Reduced bowel movements, common with opioids.
Headache: Generalized head pain.
Somnolence: Feeling unusually sleepy.
Dry mouth: Reduced saliva production.

Serious or Rare Side Effects

Respiratory depression: Slowed breathing that can be life‑threatening.
Severe hypotension: Marked drop in blood pressure.
Seizures: Uncontrolled electrical activity in the brain.
Anaphylaxis: Acute allergic reaction with hives, swelling, and airway compromise.

Precautions & Warnings

When prescribing Tapentadol Hydrochloride, clinicians should consider several safety measures.

Assess pain severity: Confirm that opioid therapy is appropriate for the patient’s level of pain.
Evaluate opioid tolerance: Determine if the patient has prior exposure to opioids.
Monitor for respiratory depression: Observe breathing, especially after dose initiation or increase.
Avoid concurrent CNS depressants: Limit use of alcohol, benzodiazepines, or other sedatives.
Educate on dependence risk: Discuss potential for misuse and proper disposal.
Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Avoid Interactions

Tapentadol Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

Benzodiazepines: Combined use can cause profound respiratory depression.
Central nervous system depressants: Concomitant use may enhance sedation and respiratory risks.
MAO inhibitors: May precipitate hypertensive crisis or serotonin syndrome.

Moderate Interactions (Monitor Closely)

Serotonergic agents: Increased risk of serotonin syndrome, especially with SSRIs or SNRIs.
CYP2D6 inhibitors: May raise tapentadol plasma levels, requiring dose adjustment.
Antihypertensives: May potentiate hypotensive effects, necessitating blood pressure monitoring.

Frequently Asked Questions

Palexia contains tapentadol hydrochloride and is prescribed to relieve moderate to severe pain, including acute postoperative pain, chronic musculoskeletal pain, and pain associated with cancer. It is used when other analgesics are insufficient or not tolerated.

Tapentadol hydrochloride provides pain relief through a dual mechanism: it activates mu‑opioid receptors for opioid‑type analgesia and inhibits norepinephrine reuptake, which enhances the body’s natural descending pain‑inhibitory pathways. This combination reduces pain perception with lower opioid receptor activation.

The appropriate dose of Palexia is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Tapentadol is classified as a pregnancy‑category medication with potential risks to the fetus and should be used only if the benefit justifies the potential harm. It is excreted in breast milk, so breastfeeding mothers should consult their healthcare provider before use.

To order Palexia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional opioids such as morphine, tapentadol offers dual‑action analgesia with potentially lower rates of some opioid‑related side effects, like severe constipation, due to its additional norepinephrine reuptake inhibition. However, it shares many class‑related risks, including respiratory depression and dependence.

Palexia should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Palexia is taken orally, usually as a tablet or capsule, and should be swallowed whole with water. It may be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals.

The most serious risks include respiratory depression, severe hypotension, seizures, and the potential for opioid dependence or abuse. Patients should be monitored closely, especially during dose initiation or when combined with other central nervous system depressants.

Palexia is contraindicated in individuals with known hypersensitivity to tapentadol or other opioids, those who have experienced severe respiratory depression, and patients taking monoamine oxidase inhibitors. It should also be avoided in patients with uncontrolled asthma or severe obstructive sleep apnea.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.